Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform as ChEMBL target CHEMBL2499, mapped to UniProt P42337. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Why Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform matters
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform is reviewed as Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (UniProt P42337); the current evidence base includes 1 approved drug, 140 compounds, and 15 assays, with lead potency reaching pChEMBL 9.7.
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Sequence length is 1068 aa.
Review this target as Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform, mapped to UniProt P42337. Sequence length is 1068 aa.
Protein source · UniProt accession via ChEMBL component mappingDisease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordChEMBL currently tracks 1 approved drug, 140 compounds, and 15 assays for this target. The dominant activity type is IC50. CHEMBL2331668 is the current potency anchor at pChEMBL 9.7.
Use CHEMBL2331668 as the tractability anchor when discussing potency (pChEMBL 9.7).
Activity source · ChEMBL 36 via Core EngineStart with the right source
Pick the first block or linked source that matches the review question in front of you.
Start with the review rationale when you need to explain why Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform matters before drilling into raw source blocks.
Jump to Review RationaleGo back to the target snapshot when you need the naming and mapping contract behind UniProt P42337, not just the summarized rationale.
Open Protein ContextUse the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL2331668
|
9.7 | Ki | — |
|
|
No preferred name
CHEMBL1911117
|
9.7 | IC50 | — |
|
|
No preferred name
CHEMBL2331664
|
9.5 | Ki | — |
|
|
No preferred name
CHEMBL2375957
|
9.5 | Ki | — |
|
|
No preferred name
CHEMBL2376096
|
9.5 | Ki | — |